Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-week Comparison of the Efficacy and Safety of Albuterol Spiromax Versus Placebo in Subjects 12 Years and Older With Persistent Asthma

Trial Profile

A 12-week Comparison of the Efficacy and Safety of Albuterol Spiromax Versus Placebo in Subjects 12 Years and Older With Persistent Asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Salbutamol (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors Teva Branded Pharmaceutical Products R&D

Most Recent Events

  • 01 Apr 2015 According to Teva Pharmaceutical Industries media release, company receives FDA approval for ProAir RespiClick (albuterol sulfate) for treatment and prevention of bronchospasm and exercise induced bronchospasm in patients 12 age and over.
  • 24 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 27 Sep 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top